GlassScriptPhysician profile
Romeeda Mohammed
NPI 1124133301
$4,764.28
in general payments reported to CMS, 2019-2025
10 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $757 · 2022: $1,052 · 2023: $1,112 · 2024: $1,144 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.14 |
| Education | $156.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,045.16 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $936.67 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $702.87 | 2021-2024 | Ingrezza |
| Abbvie INC. | $699.54 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $423.39 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $357.92 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $245.98 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $187.65 | 2021-2023 | Invega Sustenna |
| Novo Nordisk INC | $119.20 | 2022 | |
| Glaxosmithkline, LLC. | $45.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Romeeda Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.